Related Experiment Video
Updated: Oct 7, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: Findings From
Felipe H Valle1, Shaun G Goodman1,2, Mary Tan2
1Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Insights
In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual-pathway therapy is used in about a quarter of cases, with increasing use over time. This therapy is chosen for patients with less complex coronary disease histories.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Balancing antithrombotic therapy risks (ischemia, stroke, bleeding) is crucial for atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI).
- Understanding current treatment patterns is essential for optimizing patient care and outcomes in this high-risk population.
Purpose of the Study:
- To determine the patterns of initial antithrombotic therapy selection in patients with AF undergoing PCI.
- To analyze trends in the use of different antithrombotic regimens, including triple antithrombotic therapy (TAT) and dual-pathway therapy (DPT).
Main Methods:
- A chart audit of 467 patients with AF undergoing PCI between December 2015 and July 2018 was conducted.
- Data were collected by 47 Canadian cardiologists as part of the CONNECT AF+PCI study.
- Initial antithrombotic therapy selection (TAT, DPT, dual antiplatelet therapy) was analyzed.
Main Results:
- Triple antithrombotic therapy (TAT) was the initial choice for 62.7% of patients, followed by dual-pathway therapy (DPT) for 25.7%, and dual antiplatelet therapy for 11.6%.
- Use of DPT showed a temporal increase during the study period.
- Patients selected for DPT had less prior myocardial infarction and PCI but a higher prevalence of prior stroke/transient ischemic attack compared to those on TAT.
Conclusions:
- Approximately one-quarter of AF patients undergoing PCI in Canadian practice receive dual-pathway therapy (DPT).
- The utilization of DPT increased during the study period.
- Patients receiving DPT generally presented with less complex coronary disease histories and interventions.
Background:
In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), selecting an antithrombotic regimen requires balancing risks of ischemic cardiac events, stroke, and bleeding.
Methods:
We studied 467 patients with AF undergoing PCI in the time period from December 2015 to July 2018 identified via a chart audit by 47 Canadian cardiologists in the CONNECT AF+PCI (the Coordinated National Network to Engage Interventional Cardiologists in the Antithrombotic Treatment of Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) study, to determine patterns of initial antithrombotic therapy selection.
Results:
The median (25th, 75th percentile) CHADS2 score was 2 (1, 3), and PCI was performed in the setting of acute coronary syndrome in 62.1%. Triple antithrombotic therapy (TAT) was the initial treatment in 62.7%, dual-pathway therapy in 25.7%, and dual antiplatelet therapy in 11.6%, with a temporal increase in use of dual-pathway therapy during the course of the study; median intended TAT duration was 1 (1, 3) month. Compared with patients selected for TAT, patients selected for dual-pathway therapy were less likely to have prior myocardial infarction (35.8% vs 25.8%, P = 0.045) and prior PCI (33.8% vs 23.3%, P = 0.03), and they received shorter total length of stents (38 [23, 56] vs 30 [20, 46] mm, P = 0.03). Patients selected for dual-pathway therapy had a higher prevalence of prior stroke/transient ischemic attack (13.0% vs 23.3%, P = 0.01). There was no difference in prevalence of anemia (21.5% vs 25.8%, P = 0.30). Use of dual-pathway therapy was similar among patients with acute coronary syndrome and those with stable disease (24.1% vs 28.2%, P = 0.32).
Conclusions:
Approximately one-quarter of AF patients undergoing PCI are treated with dual-pathway therapy in Canadian practice, with its use increasing during the studied period. Patients selected for dual-pathway therapy have less-complex coronary disease history and intervention.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

